Transdigm Group INC Form 4 insider transactions

TransDigm Group Director W. Nicholas Howley acquired 113 shares of common stock in lieu of a director fee, increasing his direct beneficial ownership.

TransDigm Group Director W. Nicholas Howley exercised stock options and subsequently sold common stock under a pre-arranged Rule 10b5-1 plan.

TransDigm Group director Robert J. Small reported a purchase of one common stock share and resolved a Section 16(b) short-swing profit issue.

TransDigm Group's Co-Chief Operating Officer, Patrick Joseph Murphy, exercised stock options to acquire 1,460 shares of common stock.

TransDigm Group's President and CEO, Michael Lisman, acquired 950 shares of common stock at $1,284.2608 per share, increasing his direct beneficial ownership.

TransDigm Group's Chief Financial Officer, Sarah Wynne, exercised stock options to acquire 1,494 shares of common stock.

TransDigm Group Director Kevin M. Stein sold 11,075 shares of common stock for approximately $15.9 million through a pre-arranged 10b5-1 plan.

TransDigm Group director Kevin M. Stein exercised stock options and subsequently sold a significant portion of the acquired shares, as detailed in a recent SEC Form 4 filing.

TransDigm Group's Co-Chief Operating Officer, Patrick Joseph Murphy, exercised stock options and subsequently sold an equal number of common shares.

TransDigm Group's Co-Chief Operating Officer, Joel Reiss, exercised stock options and subsequently sold 3,900 shares of common stock in a pre-planned transaction.

TransDigm Group Director Kevin M. Stein exercised stock options and subsequently sold a portion of the acquired common stock through a pre-arranged 10b5-1 plan.

TransDigm Group Director Kevin M. Stein exercised stock options and subsequently sold an equivalent number of shares through a trust.

TransDigm Group Director Kevin Stein executed pre-planned transactions, exercising stock options and selling an equivalent number of common shares.

TransDigm Group's Co-Chief Operating Officer, Patrick Joseph Murphy, exercised stock options and subsequently sold an equal number of common shares.

TransDigm Group's Co-Chief Operating Officer, Joel Reiss, exercised stock options and subsequently sold a net of 120 common shares under a Rule 10b5-1 plan.

TransDigm Group director Robert J. Small exercised stock options and subsequently sold 4,700 shares of common stock for over $6 million on December 10, 2025.

TransDigm Group Director Robert J. Small reported the sale of 90,953 shares of common stock for approximately $121.4 million.

TransDigm Group Director Kevin M Stein exercised stock options and subsequently sold a portion of the acquired common stock through a pre-arranged trading plan.

TransDigm Group's Co-Chief Operating Officer, Patrick Joseph Murphy, exercised stock options and subsequently sold a portion of his common stock holdings under a 10b5-1 plan.

TransDigm Group Director Kevin M. Stein exercised stock options and subsequently sold an equal number of shares through a pre-arranged 10b5-1 plan.

TransDigm Group Director Kevin Stein exercised stock options and subsequently sold a portion of the acquired shares for a significant profit under a Rule 10b5-1 plan.

TransDigm Group Director Michael Graff has filed a Form 4 indicating a planned future gift of 340 shares of common stock to a trust on November 21, 2025, under a Rule 10b5-1 plan.

TransDigm Group Director Kevin M. Stein executed a pre-planned sale of 230 common shares following an option exercise, as disclosed in a recent SEC Form 4 filing.

TransDigm Group Director Kevin Stein exercised stock options and subsequently sold an equivalent number of shares through a pre-planned trading arrangement.

TransDigm Group Director Kevin Stein exercised stock options and subsequently sold an equal number of shares under a pre-arranged plan.

TransDigm Co-COO Joel Reiss exercised 3,900 options at $284.97 and sold the resulting shares via a Rule 10b5-1 plan, reducing direct holdings to 3,600 shares.

TransDigm Group's President and CEO, Michael Lisman, acquired 1,954 shares of common stock totaling approximately $2.6 million through a trust.

TransDigm Group Director W. Nicholas Howley exercised stock options and subsequently sold a portion of his common stock holdings through a pre-arranged 10b5-1 plan.

TransDigm Group Director David Barr was granted 518 stock options with an exercise price of $1,291.97, vesting over five years based on performance targets.

TransDigm Group Director Jane M. Cronin was granted 518 performance-based stock options with an exercise price of $1,291.97, vesting over five years.